Omeros (OMER) Competitors $10.42 +6.32 (+154.15%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$9.24 -1.18 (-11.35%) As of 05:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OMER vs. NKTR, PCRX, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMYShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Its Competitors Nektar Therapeutics Pacira BioSciences Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Which has more volatility and risk, OMER or NKTR? Omeros has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Is OMER or NKTR more profitable? Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -163.17%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -55.49% Nektar Therapeutics -163.17%-631.43%-58.21% Do analysts prefer OMER or NKTR? Omeros currently has a consensus price target of $27.50, suggesting a potential upside of 163.92%. Nektar Therapeutics has a consensus price target of $91.67, suggesting a potential upside of 61.16%. Given Omeros' stronger consensus rating and higher probable upside, equities analysts clearly believe Omeros is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.75Nektar Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the media refer more to OMER or NKTR? In the previous week, Omeros had 16 more articles in the media than Nektar Therapeutics. MarketBeat recorded 23 mentions for Omeros and 7 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.14 beat Omeros' score of 0.53 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 6 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, OMER or NKTR? Nektar Therapeutics has higher revenue and earnings than Omeros. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$156.82M-$2.11-4.94Nektar Therapeutics$98.43M10.99-$118.96M-$8.80-6.46 Do insiders and institutionals hold more shares of OMER or NKTR? 48.8% of Omeros shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 12.9% of Omeros shares are held by company insiders. Comparatively, 5.3% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryOmeros beats Nektar Therapeutics on 11 of the 16 factors compared between the two stocks. Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.03M$10.68B$6.11B$10.45BDividend YieldN/A1.91%5.73%4.77%P/E Ratio-4.9420.5185.4027.36Price / SalesN/A26.73599.20137.65Price / CashN/A25.0737.4661.86Price / Book-3.313.4812.446.81Net Income-$156.82M$208.83M$3.32B$276.80M7 Day Performance128.51%-0.59%0.60%0.42%1 Month Performance158.56%3.16%10.53%7.86%1 Year Performance151.69%-6.35%73.12%41.24% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros4.0392 of 5 stars$10.42+154.1%$27.50+163.9%+153.5%$279.03MN/A-4.94210Trending NewsAnalyst ForecastGap UpHigh Trading VolumeNKTRNektar Therapeutics4.0831 of 5 stars$59.93-1.0%$91.67+53.0%+194.0%$1.15B$98.43M-6.81220PCRXPacira BioSciences3.7953 of 5 stars$23.87-3.9%$33.40+39.9%+40.5%$1.12B$700.97M-8.59720Positive NewsASMBAssembly Biosciences3.7208 of 5 stars$24.48+5.0%$41.25+68.5%+53.6%$178.92M$28.52M-4.39100Analyst ForecastCPIXCumberland Pharmaceuticals1.0875 of 5 stars$3.09-1.3%N/A+175.2%$46.83M$37.87M-14.0580LLYEli Lilly and Company4.9964 of 5 stars$845.40+0.7%$938.94+11.1%-9.6%$794.90B$45.04B55.2547,000Trending NewsAnalyst UpgradeAnalyst RevisionJNJJohnson & Johnson4.7513 of 5 stars$188.23-0.2%$189.12+0.5%+16.3%$454.31B$88.82B20.13138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastABBVAbbVie4.6447 of 5 stars$230.28-1.6%$228.22-0.9%+18.0%$413.22B$56.33B109.6655,000Trending NewsAnalyst ForecastOptions VolumeAnalyst RevisionMRKMerck & Co., Inc.4.9978 of 5 stars$88.83-0.4%$106.41+19.8%-24.6%$222.78B$63.62B13.6975,000Trending NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.9768 of 5 stars$26.45-3.4%$28.41+7.4%-17.2%$155.61B$63.63B14.0781,000Trending NewsDividend AnnouncementAnalyst RevisionBMYBristol Myers Squibb4.9862 of 5 stars$45.16-0.6%$56.38+24.8%-17.3%$92.51B$48.30B18.2134,100Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies NKTR Alternatives PCRX Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMER) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
